These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20189234)

  • 21. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
    Tebes SJ; Sayer RA; Palmer JM; Tebes CC; Martino MA; Hoffman MS
    Gynecol Oncol; 2007 Sep; 106(3):482-7. PubMed ID: 17590420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction.
    Mahner S; Woelber L; Jung S; Eulenburg CZ; Ihnen M; Schwarz J; Sehouli J; Jaenicke F
    Anticancer Res; 2009 Jul; 29(7):2817-21. PubMed ID: 19596967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.
    Munkarah A; Levenback C; Wolf JK; Bodurka-Bevers D; Tortolero-Luna G; Morris RT; Gershenson DM
    Gynecol Oncol; 2001 May; 81(2):237-41. PubMed ID: 11330956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy.
    Kapp KS; Kapp DS; Poschauko J; Stücklschweiger GF; Hackl A; Pickel H; Petru E; Winter R
    Gynecol Oncol; 1999 Sep; 74(3):400-7. PubMed ID: 10479500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
    Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
    Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
    Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
    Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent ovarian carcinoma of low malignant potential: the role of secondary surgical cytoreduction and the prognosis in Chinese patients.
    Zang RY; Yang WT; Shi DR; Xing Y; Cai SM
    J Surg Oncol; 2005 Jul; 91(1):67-72. PubMed ID: 15999350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer].
    Li YF; Li MD; Liu FY; Liu JH; Li JD
    Ai Zheng; 2003 Nov; 22(11):1193-6. PubMed ID: 14613651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
    Santillan A; Karam AK; Li AJ; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Bristow RE
    Gynecol Oncol; 2007 Mar; 104(3):686-90. PubMed ID: 17141302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery.
    Usami T; Kato K; Taniguchi T; Abe A; Nomura H; Yamamoto A; Matoda M; Okamoto S; Kondo E; Omatsu K; Kawamata Y; Takeshima N
    Int J Gynecol Cancer; 2014 Jul; 24(6):991-6. PubMed ID: 24905612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis.
    Harter P; Hahmann M; Lueck HJ; Poelcher M; Wimberger P; Ortmann O; Canzler U; Richter B; Wagner U; Hasenburg A; Burges A; Loibl S; Meier W; Huober J; Fink D; Schroeder W; Muenstedt K; Schmalfeldt B; Emons G; du Bois A
    Ann Surg Oncol; 2009 May; 16(5):1324-30. PubMed ID: 19225844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.
    Di Giorgio A; Naticchioni E; Biacchi D; Sibio S; Accarpio F; Rocco M; Tarquini S; Di Seri M; Ciardi A; Montruccoli D; Sammartino P
    Cancer; 2008 Jul; 113(2):315-25. PubMed ID: 18473354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surgical technique of diaphragm full-thickness resection and trans-diaphragmatic decompression of pneumothorax during cytoreductive surgery for ovarian cancer.
    Bashir S; Gerardi MA; Giuntoli RL; Montes TP; Bristow RE
    Gynecol Oncol; 2010 Nov; 119(2):255-8. PubMed ID: 20739051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Oliva GD; Laterza B; Deraco M
    Ann Surg Oncol; 2007 Oct; 14(10):2790-7. PubMed ID: 17661150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.
    Munkarah AR; Coleman RL
    Gynecol Oncol; 2004 Nov; 95(2):273-80. PubMed ID: 15491746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
    J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
    Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
    Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator.
    Bristow RE; Montz FJ
    Gynecol Oncol; 2001 Oct; 83(1):39-48. PubMed ID: 11585412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.